Continental AG Shares Jump After Q1 Profit Beats Expectations 
BHP Attracts AI-Focused Investors as Copper Demand Surges 
Aker BP Q1 Profit Jumps on Higher Oil Prices and Asset Reversal 
Shell Q1 Profit Surges to Two-Year High as Dividend Rises Despite War-Driven Debt Pressure 
Lufthansa Q1 Loss Narrows as Strong Summer Travel Demand Boosts Outlook 
Intel Emerges as Key Contender in Apple’s Chip Manufacturing Strategy Shift 
Supermicro Forecasts Strong Q4 Revenue Growth as AI Server Demand Surges 
Volvo Car Sales Drop 10% in Early 2026 Despite Growth in Electric Vehicles 
Novo Nordisk Raises 2026 Outlook on Strong Wegovy Demand 
BMW Keeps 2026 Outlook Despite 25% Profit Drop Amid Tariff Pressure 
Orsted Q1 EBITDA Beats Expectations Despite U.S. Impairments 
Hugo Boss Beats Q1 Profit Expectations Despite Market Headwinds 
Rivian Hints at New R2 Variants as Production Ramps Up Ahead of 2027 Launch 
Maersk Q1 Earnings Beat Expectations as Iran Conflict Clouds Shipping Outlook 
Palantir Reports Record Growth, Raises 2026 Revenue Outlook Above Expectations 
Infineon Raises 2026 Outlook as AI Data Center Chip Demand Surges 
Pinterest Stock Surges After Strong Q1 2026 Earnings Beat Expectations 
DURHAM, N.C., April 30, 2018 -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals for the growing population of immunocompromised patients, today announced that it will host a live conference call and audio webcast on Monday, May 7, 2018 at 8:30 a.m. ET to report financial results for the first quarter ended March 31, 2018, and to provide a business overview.
To access the live conference call, please dial (877) 354-4056 (domestic) or (678) 809-1043 (international) at least five minutes prior to the start time and refer to conference ID 6173279. A live audio webcast of the call and accompanying slide presentation will also be available on the Investors’ section of the Company's website, www.chimerix.com. An archived webcast and accompanying slides will be available on the Chimerix website approximately two hours after the event.
About Chimerix
Chimerix is a biopharmaceutical company dedicated to discovering, developing and commercializing medicines that improve outcomes for immunocompromised patients. Chimerix's proprietary lipid conjugate technology and compound library have produced brincidofovir (BCV, CMX001); CMX157, which was licensed to ContraVir Pharmaceuticals; and a new clinical candidate, CMX521, the first direct-acting antiviral specifically for the treatment and prevention of norovirus. For further information, please visit Chimerix's website, www.chimerix.com.
CONTACT:
Investor Relations:
Michelle LaSpaluto
(919) 972-7115
[email protected]
or
Will O’Connor
Stern Investor Relations
[email protected]
212-362-1200
Media:
Becky Vonsiatsky
W2O Group
[email protected]
413-478-2003
